Suppression of tumor-suppressive signaling (WNT/β-catenin and TGF-β regulation) and dysregulation of immune pathways (IL-6, IFN-α/β, and Th17 signaling) were observed, collectively favoring a microenvironment conducive to malignant transformation. The gene discussed is TGFB1; the disease is neoplasm.